Hanall Biopharma announced on the 9th that its U.S. partner Imunovant will expand the development of HL161 (code name IMVT-1401), which is being developed as a SC autoimmune treatment.

Phase 3 clinical trials for severe work history will begin this month and the results of the top line in 2024 will be confirmed. According to Immunovant, there are estimated to be about 66,000 patients with severe work history in the United States.

Clinical plans for TED, which were suspended last year, have also been unveiled. Immunovant obtained consent from the U.S. Food and Drug Administration (FDA) for phase 3 clinical trials of HL161. Phase 3 clinical trials are expected to begin in the second half of th